Archives
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Astrocyte Heterogeneity Across Space and Time
2026-10-01
Schroeder et al. developed a cross-species, developmental single-nucleus transcriptomic atlas showing that astrocytes retain strong regional identities while their molecular programs change substantially after birth. The study combines transcriptomic comparisons with expansion microscopy, linking conserved and divergent gene-expression patterns to regionally specialized astrocyte morphology.
-
Leptin Fragments in Metabolic Inflammation
2026-10-01
Leptin (116-130), amide, mouse provides a focused way to interrogate leptin biology in obesity, diabetes, and immunometabolic research. This article connects fragment-based experimental design with recent evidence on SIRT6-AMPK signaling, NLRP3 inflammasome activity, and atrial remodeling while distinguishing established findings from translational hypotheses.
-
How Dual-Action Inhibitors Tune p38α Dephosphorylation
2026-09-30
A bioRxiv preprint by Stadnicki and colleagues shows that selected p38α inhibitors can do more than block catalytic activity: they can also accelerate WIP1-mediated removal of the activation-loop phospho-threonine. Biochemical measurements and X-ray structures connect this effect to an inhibitor-stabilized activation-loop conformation that exposes the phosphatase-sensitive site, suggesting a strategy for more durable and selective kinase control.
-
FITC Goat Anti-Rabbit IgG (H+L) Antibody Workflow
2026-09-30
Build sensitive immunofluorescence, flow cytometry, and fluorescent tissue-detection workflows around a fluorescein-conjugated secondary antibody. This guide connects practical assay controls and optimization decisions with IL-11/GP130 fibrosis research without implying that the reference study used this specific reagent.
-
LG 101506: Reframing RXR Signaling for Translation
2026-09-29
A thought-leadership framework for using LG 101506 as a precise RXR modulator in nuclear receptor signaling, immunometabolic research, and hypothesis-driven studies of immune-cold tumor biology.
-
Cy5 Goat Anti-Mouse IgG (H+L) Guide
2026-09-29
This scenario-driven guide explains how Cy5 Goat Anti-Mouse IgG (H+L) Antibody, SKU K1210, can improve mouse IgG detection in immunocytochemistry, immunohistochemistry, and flow cytometry workflows. It emphasizes controls, optimization, storage, interpretation, and practical vendor-selection criteria for cell viability, proliferation, and cytotoxicity studies.
-
CELLFIE Reveals CRISPR-Boosted CAR T Cell Design
2026-09-28
The reference study introduces CELLFIE, a high-content CRISPR screening platform designed to identify genetic perturbations that improve CAR T cell performance across clinically relevant failure modes. Genome-wide, in vivo, combinatorial, and base-editing experiments highlighted RHOG, PRDM1, and FAS, with RHOG disruption—especially alongside FAS loss—emerging as a notable strategy for enhancing antitumour activity.
-
DAPI (hydrochloride) for Host–Pathogen Assays
2026-09-28
Learn how to use DAPI (hydrochloride) to visualize and quantify DNA in cell-based studies inspired by erythrocyte-mimicking nanovesicle research on periodontitis. The guide separates what the published study demonstrated from practical staining workflows, with starting conditions and troubleshooting for imaging and flow cytometry.
-
Adenosine Triphosphate for Mitochondrial Metabolism
2026-09-27
Use ATP as a carefully controlled reagent to connect mitochondrial metabolic changes with cellular energy readouts—without mistaking a bulk ATP measurement for a specific OGDH assay. This workflow pairs practical ATP handling with the 2025 discovery that TCAIM can lower OGDH protein levels through mitochondrial proteostasis.
-
2-NBDG Glucose Uptake Assay Kit: Research Guide
2026-09-26
The 2-NBDG Glucose Uptake Assay Kit measures cellular accumulation of a fluorescent glucose analogue without radioactivity. It can complement, but does not reproduce, the lipid-metabolism and ferroptosis analyses reported in the 2024 HCC sorafenib-resistance study.
-
HNF4A-AS1, Lipid Metabolism, and Sorafenib Resistance
2026-09-25
A 2024 study links low HNF4A-AS1 to sorafenib resistance in hepatocellular carcinoma through METTL3-dependent m6A modification of DECR1 mRNA, reduced PUFA abundance, and weaker ferroptosis. Its combined cell, organoid, xenograft, and molecular analyses provide a mechanistic framework for studying lipid-metabolism-driven treatment response, while leaving clinical validation as an important next step.
-
G-1 for GPR30 Immune and Cardiac Assays
2026-09-25
Use G-1 to isolate rapid GPR30 signaling from classical estrogen-receptor effects, then connect receptor activation to functional immune, migration, or cardiac readouts. This guide pairs the hemorrhagic-shock immune workflow with practical controls, compound-handling advice, and clear limits on transferring results between models.
-
740 Y-P: Practical PI 3-Kinase Activation
2026-09-24
740 Y-P is a PI 3-kinase activator for researchers testing PI3K/AKT pathway responses, including vesicular trafficking, cell survival, and cancer research models. Use it as an experimental perturbation with matched vehicle and endpoint controls; do not treat dossier examples as a universally validated dose or as evidence of clinical effect.
-
Sildenafil Citrate: From cGMP to Assay Design
2026-09-24
Sildenafil Citrate is more than a cGMP-pathway probe: its effects can depend on the biological context and the assay used to measure them. Learn how to connect PDE5 inhibition, downstream signaling, and proteoform-aware target engagement without overinterpreting experimental results.
-
MLN8237 (Alisertib): Practical Aurora A Workflows
2026-09-23
Use MLN8237 (Alisertib) to test how Aurora A activity shapes mitosis, survival, and tumor-cell responses—not simply to generate a viability value. This guide turns retinoblastoma findings into a staged workflow with practical controls, dose-and-time optimization, and troubleshooting for preclinical cancer biology.